Ascendis Pharma A/S Research And Development Expense

Quick Answer

Ascendis Pharma A/S reported Research And Development Expense of $303.62 million for the year ending 2025.

  • Ascendis Pharma A/S showed a decrease of -1.1% in Research And Development Expense from 2024 to 2025.
  • This data is from Ascendis Pharma A/S's annual report (Form 10-K), filed with the SEC on February 11, 2026.
  • XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 11 years of available data (2015 to 2025), Ascendis Pharma A/S's Research And Development Expense has grown by 649.2%.
  • Historical annual values: Fiscal year 2025: $303.62 million | Fiscal year 2024: $307.00 million | Fiscal year 2023: $413.45 million | Fiscal year 2022: $379.62 million | Fiscal year 2021: $295.87 million | Fiscal year 2020: $260.90 million | Fiscal year 2019: $191.62 million | Fiscal year 2018: $140.28 million | Fiscal year 2017: $99.59 million | Fiscal year 2016: $66.02 million | Fiscal year 2015: $40.53 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: